Clinical Trial

Psilocybin Therapy for Depression in Parkinson's Disease

Study acronym: PDP2
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-06-06; most recent amendment 2026-05-29.
Status change: Not Yet Recruiting → Recruiting 2024-08-19
Trial Details
NCT Number NCT06455293
Lead Sponsor Joshua Woolley, MD, PhD
Conditions Parkinson Disease, Depression
Enrollment 60 participants
Start Date 2024-08-19
Primary Completion 2027-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-07